Daemon57 and Misiu143
Cytodyn: Partner, Buyout, Overseas, >> The road ahead here is really "rocky." Our problem is still the lack of BUZZ (the..."yeah, I heard somethin' about that..." factor). Things have grown in leaps and bounds but except in a few circles, CytoDyn, Leronlimab, Vyrologix is still largely unknown.
In the current environment the FDA can "dump rocks" in front of Cytodyn Inc. because it's not under any kind of spotlight.
Now if we could "nudge" the light's focus a little, BP would throw the FDA under the bus, "We were aghast to hear there was thought to be some kind of favoritism..." or some-such thing.
Several have written letters about leronlimab's efficacy, including me, but I believe without the ground-swell, while probably annoying, the recipients move full-speed ahead. Perhaps a slightly different audience is the key. One that would react either with enthusiasm or as a CYA 'try to get out in front the furor'. The cool thing is, I believe Cytodyn could survive the scrutiny (and if it can't - I'd be surprised but would react), meanwhile some other entities could get deservedly "rocked."
Speaking of rocks, for a brief period, Cytodyn would be "golden," but we're dealing with long memories, unless Cytodyn decides to "share" a little (like sprinkling contractual twinkie dust here and there).
And this approach is not devious, total honesty, just get the truth out and allow the sizzle to sell itself.
There's a few I'd like to review the doc and target aud. - my biggest problem is getting near a computer during the 4-5 pm Friday time. I'd appreciate your "take"
AI
Market Data 
Markets 
